Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£120.10 -622.00 (-4.92%)
As of 06:55 AM Eastern
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings
Sell
1
Hold
0
Buy
5

Based on 6 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a sell rating, and 5 have given a buy rating for AZN.

Consensus Price Target

£152.17
According to the 6 analysts' twelve-month price targets for AstraZeneca, the average price target is £152.17. The highest price target for AZN is £178, while the lowest price target for AZN is £115. The average price target represents a forecasted upside of 26.70% from the current price of £120.10.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
8/3/25 to 8/3/26		1 Month Ago
7/4/25 to 7/4/26		3 Months Ago
5/5/25 to 5/5/26		1 Year Ago
8/3/24 to 8/3/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£152.17£153.33£153.33GBX 9,660
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaHealthcare Companies
Consensus Rating Score
2.67
2.31
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/3/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuy£175+47.85%
7/28/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Reiterated RatingSell£115-11.93%
7/28/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
 Boost TargetBuy£175 ➝ £178+39.50%
7/28/2026
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy£160+25.39%
1/16/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/15/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:23 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 27, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • The recent approval of Enhertu for HER2-positive metastatic solid tumors has expanded AstraZeneca's oncology portfolio, potentially increasing revenue from this high-demand area.
  • AstraZeneca's stock has shown positive momentum, with a recent increase of approximately 5.9%, indicating strong investor sentiment and confidence in the company's future prospects.
  • The company is advancing its oral GLP-1 candidate, elecoglipron, into Phase III development, which could lead to significant market opportunities in the diabetes treatment sector.
  • AstraZeneca operates in over 100 countries, providing a diversified revenue stream and reducing reliance on any single market, which can mitigate risks associated with regional downturns.
  • The current stock price is around $XX, reflecting a favorable valuation compared to its peers in the pharmaceutical industry, making it an attractive investment option.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • Despite recent approvals, the pharmaceutical industry is highly competitive, and AstraZeneca faces significant challenges from other companies developing similar oncology treatments.
  • Regulatory hurdles can delay product launches and approvals, which may impact AstraZeneca's ability to capitalize on its pipeline effectively.
  • Market volatility can affect stock performance, and any negative news related to clinical trials or product efficacy could lead to sharp declines in stock value.
  • Investors may be concerned about the sustainability of growth, as the pharmaceutical sector often experiences fluctuations based on patent expirations and generic competition.
  • While the stock has recently rallied, past performance does not guarantee future results, and investors should be cautious of potential corrections in the market.

AZN Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £152.17, with a high forecast of £178 and a low forecast of £115.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 26.70% based on their 12-month stock forecasts.

Over the previous 90 days, AstraZeneca's stock had 1 downgrade by analysts.

AstraZeneca has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, and Jefferies Financial Group in the past 90 days.

Analysts like AstraZeneca more than other "healthcare" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how AZN compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations


This page (LON:AZN) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel